Statistics for Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis.
Total visits
views | |
---|---|
Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%: EMPOWER-Lung 1 subgroup analysis. | 0 |
Total visits per month
views | |
---|---|
November 2023 | 0 |
December 2023 | 0 |
January 2024 | 0 |
February 2024 | 0 |
March 2024 | 0 |
April 2024 | 0 |
May 2024 | 0 |